The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia

Seung Wook Hong; Byong Duk Ye

doi:10.5217/ir.2020.00121

Articles

Page Path: HOME > Intest Res > Volume 18(4); 2020 > Article

Editorial The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia: Seung Wook Hong¹, Byong Duk Ye^1,2; Intestinal Research 2020;18(4):345-346.
DOI: https://doi.org/10.5217/ir.2020.00121
Published online: October 26, 2020

¹Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

²Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence to Byong Duk Ye, Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Tel: +82-2-3010-3181, Fax: +82-2-476-0824, E-mail: bdye@amc.seoul.kr

• Received: October 7, 2020 • Accepted: October 8, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

5,892 Views
132 Download
14 Web of Science
14 Crossref
11 Scopus

Full Article

Download PDF

NOTES
REFERENCES

See the article "Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study" on page 430.

See Article on [Related article:] 430

Inflammatory bowel disease (IBD) is a disease in which the burden is rising worldwide [1]. IBD is most commonly diagnosed in the second to fourth decade of life, and it impairs numerous aspects of an individual’s life [2]. Although the pathogenesis of IBD remains unclear, it is believed to be the consequence of an unregulated inflammatory response to the gut microbiome in a genetically susceptible host [3]. Additionally, it is postulated that multiple environmental factors play significant roles in the development of IBD [3]. In this aspect, epidemiological studies in various parts of the world could provide either direct or indirect insights into the impact of environmental factors in the development of IBD. Traditionally, IBD has been considered a common disease in high-income regions, such as North America, Western Europe, and Oceania. However, recent epidemiologic reports have shown a rapid rise in IBD incidence in the newly industrialized countries in Eastern Europe, Asia, and South America [4-7]. Although the exact cause of the increase in IBD in previously low-incidence regions is still unclear, Westernization of society is believed to be associated with the accelerating incidence of IBD, making it a global disease [4]. However, there have been no formal reports on the epidemiology of IBD in Central Asia, a large area in the middle of the Eurasian continent.

In the present issue of Intestinal Research, Kaibullayeva et al. [8] first reported the prevalence of IBD in Kazakhstan. The authors enrolled a total of 115,556 subjects between January 2017 and December 2017 and confirmed 128 cases of IBD: 92 ulcerative colitis (UC) and 36 Crohn’s disease (CD). Of the 128 patients, up to 20% (25 patients) were unaware of their diagnosis. The age- and sex-adjusted prevalence of IBD was 113.9 (69.0–158.9) per 100,000 population, including 84.4 (44.8–123.9) for UC and 29.5 (8.2–50.9) for CD per 100,000 population. This estimated prevalence was much higher than that reported by the Ministry of Health of Kazakhstan (31.5 for UC and 6.3 for CD per 100,000 population). The authors presumed that the causes of these discrepancies arose from the differences in database systems and the accessibility to gastroenterological care. This study is noteworthy because the epidemiologic issues regarding IBD in Central Asia have rarely been addressed. Although this epidemiologic study could be positioned as the cornerstone of IBD epidemiological research in Central Asia, several issues should be considered when interpreting the results of this study.

First, the prevalence of IBD in this study was likely to be underestimated compared to the actual figure. Although the authors conducted a survey using questionnaires of more than 100,000 subjects from polyclinics, companies, and universities, the survey was limited to people aged 18 years and older, thereby possibly missing IBD patients in pediatric and adolescent age groups. Selection bias could also have been inherent in the study design by including only those who consented to the survey. Moreover, it is uncertain whether the distribution of age and sex in the survey respondents reflects the true population.

Second, after the survey, a confirmatory diagnosis of IBD was made sequentially by gastroenterological evaluation, fecal calprotectin test, and endoscopic and histologic evaluation. With this approach, savings in time and cost of the study could have been achieved. However, only a single test of fecal calprotectin and no incorporation of small bowel radiologic evaluation in the diagnostic algorithm might have missed true IBD patients with minimal to mild symptoms and patients with CD limited to the proximal small bowel.

Third, the authors compared the prevalence of IBD stratified into urban and rural areas, showing a numerically higher prevalence of both UC and CD in urban areas. However, there was a lack of socio-economic information to explain this regional discrepancy. For example, detailed information on the annual number of visits to healthcare facilities and household income by region could have disclosed the cause of urban-rural differences in IBD prevalence in more detail.

In conclusion, despite several limitations, this study has clinical significance because it is the first formal scientific report on the prevalence and characteristics of IBD in Central Asia. It also proposes a need to develop a strategy to enhance awareness of IBD in this region. Further studies on the evolving incidence of and risk factors for IBD in increasingly industrialized and urbanized societies are expected to provide novel insights into the etiopathogenesis of IBD.

NOTES

FINANCIAL SUPPORT

The authors received no financial support for the research, authorship, and/or publication of this article.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTION

Writing - original draft: Hong SW. Writing - review & editing: Ye BD. Approval of final manuscript: all authors.

REFERENCES

1. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:17–30.Article PubMed
2. Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care 2017;44:673–692.Article PubMed
3. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627–1640.Article PubMed
4. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–2778.Article
5. Lakatos L, Mester G, Erdelyi Z, et al. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 2004;10:404–409.Article PubMed PMC
6. Park SH, Kim YJ, Rhee KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015. J Crohns Colitis 2019;13:1410–1417.Article PubMed PDF
7. Kotze PG, Underwood FE, Damião AOMC, et al. Progression of inflammatory bowel diseases throughout Latin America and the Caribbean: a systematic review. Clin Gastroenterol Hepatol 2020;18:304–312.Article PubMed
8. Kaibullayeva J, Ualiyeva A, Oshibayeva A, Dushpanova A, Marshall JK. Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study. Intest Res 2020;18:430–437.Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Long-Term Safety of Tofacitinib for Treatment of Moderate-to-Severe Ulcerative Colitis: Three Years of Korean National Data
Eun Mi Song, Gi Hyeon Seo, Sung Hoon Jung
Journal of Korean Medical Science.2025;[Epub] CrossRef
Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors
Sang Un Kim, Hyun Seok Lee
The Korean Journal of Gastroenterology.2024; 84(2): 35. CrossRef
Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
Clinical Endoscopy.2023; 56(2): 239. CrossRef
Impact of Crohn’s Disease on the Survival of Patients with Small-Bowel Adenocarcinoma in Korea: A Bicenter Cohort Study
Kyuwon Kim, Kookhwan Choi, Sung Wook Hwang, Jong Pil Im, Byong Duk Ye, Joo Sung Kim, Kyu Joo Park, Suk-Kyun Yang, Seong-Joon Koh, Sang Hyoung Park
Gut and Liver.2023; 17(4): 581. CrossRef
Diagnosis of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Han Hee Lee, Jae Jun Park, Bo-In Lee, Ida Hilmi, Jose Sollano, Zhi Hua Ran
Intestinal Research.2023; 21(3): 328. CrossRef
Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study
Xuejie Chen, Xin Xiang, Weitong Xia, Xindi Li, Sidan Wang, Shuyu Ye, Li Tian, Lian Zhao, Feiyan Ai, Zhaohua Shen, Kai Nie, Minzi Deng, Xiaoyan Wang
Journal of Epidemiology and Global Health.2023; 13(4): 725. CrossRef
The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database
Gi Hyeon Seo, Sung Hoon Jung
Journal of Korean Medical Science.2022;[Epub] CrossRef
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intestinal Research.2022; 20(2): 159. CrossRef
Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Clostridioides Infection in Patients with Inflammatory Bowel Disease
Mi Rae Lee, Eun Soo Kim
The Korean Journal of Gastroenterology.2022; 80(2): 66. CrossRef
Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
BMC Gastroenterology.2021;[Epub] CrossRef
Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?
Soo-Young Na, Yun-Jeong Lim
Diagnostics.2021; 11(12): 2240. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia

Intest Res. 2020;18(4):345-346. Published online October 26, 2020

DOI: https://doi.org/10.5217/ir.2020.00121

XML Download

Related articles

The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia